3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
A dose defining study of the protease inhibitor tipranavir (TPV), boosted with low dose
ritonavir (RTV). Three dose combinations of TPV/RTV are administered to multiple
antiretroviral experienced patients and the dose that achieves the best efficacy and safety
as determined by evaluation of 2, 8, and 24-week virologic response and adverse event and
laboratory profile measures would be selected for further clinical study.